GlassScriptPhysician profile
Anne J Stump
NPI 1366489734
$1,972.84
in general payments reported to CMS, 2019-2025
20 companies · $472 in 2025
The $472 reported for 2025 was more than what 91% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $147 · 2021: $151 · 2022: $354 · 2023: $159 · 2024: $421 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $306.19 | 2021-2025 | Azstarys |
| Tris Pharma INC | $269.34 | 2019-2024 | Dyanavel Xr |
| Sanofi Pasteur INC. | $254.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $235.58 | 2023-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Pfizer INC. | $162.56 | 2019-2025 | |
| Neos Therapeutics, LP | $124.71 | 2019-2025 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $110.37 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Supernus Pharmaceuticals, INC. | $102.90 | 2021-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $84.50 | 2019-2024 | |
| Adlon Therapeutics L.P. | $72.08 | 2020-2021 | |
| Kaleo, INC. | $38.47 | 2021-2024 | Auvi-Q |
| Seqirus USA INC | $32.06 | 2021-2022 | |
| Cranial Technologies, INC | $30.66 | 2019-2024 | Doc Band |
| Collegium Pharmaceutical, INC. | $29.83 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $29.35 | 2019-2025 | Relexxii |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.99 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.11 | 2024 | Flumist Quadrivalent |
| Verrica Pharmaceuticals INC. | $16.41 | 2024 | Ycanth |
| Sobi, INC | $14.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Stump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.